[go: up one dir, main page]

EA201792641A1 - Ингибитор оси igfbp3/tmem219 и диабет - Google Patents

Ингибитор оси igfbp3/tmem219 и диабет

Info

Publication number
EA201792641A1
EA201792641A1 EA201792641A EA201792641A EA201792641A1 EA 201792641 A1 EA201792641 A1 EA 201792641A1 EA 201792641 A EA201792641 A EA 201792641A EA 201792641 A EA201792641 A EA 201792641A EA 201792641 A1 EA201792641 A1 EA 201792641A1
Authority
EA
Eurasian Patent Office
Prior art keywords
diabetes
igfbp3
tmem219 axis
axis inhibitor
tmem219
Prior art date
Application number
EA201792641A
Other languages
English (en)
Other versions
EA033821B1 (ru
Inventor
Франческа Д'Аддио
Паоло Фьорина
Original Assignee
Оспедале Сан Раффаэле Срл
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Оспедале Сан Раффаэле Срл filed Critical Оспедале Сан Раффаэле Срл
Publication of EA201792641A1 publication Critical patent/EA201792641A1/ru
Publication of EA033821B1 publication Critical patent/EA033821B1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4745—Insulin-like growth factor binding protein
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/04—Endocrine or metabolic disorders
    • G01N2800/042—Disorders of carbohydrate metabolism, e.g. diabetes, glucose metabolism
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/50—Determining the risk of developing a disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Endocrinology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Biophysics (AREA)
  • Pathology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Microbiology (AREA)

Abstract

Настоящее изобретение относится к роли оси IGFBP3/TMEM219 в дебюте диабета и связанному с ней применению ингибиторов оси IGFBP3/TMEM219 для лечения и/или профилактики диабета. Изобретение также относится к способу идентификации индивидуума с риском развития диабета типа 1 и/или типа 2 и связанному с ним набору.
EA201792641A 2015-06-04 2016-06-06 Применение ингибитора оси igfbp3/tmem219 для лечения диабета EA033821B1 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP15170679 2015-06-04
EP16169222 2016-05-11
PCT/EP2016/062792 WO2016193497A1 (en) 2015-06-04 2016-06-06 Inhibitor of igfbp3/tmem219 axis and diabetes

Publications (2)

Publication Number Publication Date
EA201792641A1 true EA201792641A1 (ru) 2018-03-30
EA033821B1 EA033821B1 (ru) 2019-11-29

Family

ID=56121063

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201792641A EA033821B1 (ru) 2015-06-04 2016-06-06 Применение ингибитора оси igfbp3/tmem219 для лечения диабета

Country Status (12)

Country Link
US (3) US20180169184A1 (ru)
JP (1) JP6360265B2 (ru)
KR (1) KR101978765B1 (ru)
CN (1) CN107921132B (ru)
AU (1) AU2016272045B2 (ru)
BR (1) BR112017025998A2 (ru)
CA (1) CA2988011C (ru)
EA (1) EA033821B1 (ru)
IL (1) IL256096B (ru)
MX (1) MX367312B (ru)
NZ (1) NZ738389A (ru)
WO (1) WO2016193497A1 (ru)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ738100A (en) * 2015-06-04 2019-09-27 Ospedale San Raffaele Srl Igfbp3 and uses thereof
AU2016272045B2 (en) * 2015-06-04 2018-04-19 Ospedale San Raffaele Srl Inhibitor of IGFBP3/TMEM219 axis and diabetes
KR101943382B1 (ko) 2017-09-19 2019-01-29 오토텔릭바이오 주식회사 Sglt-2 저해제 및 안지오텐신 수용체 차단제를 포함하는 의약 조성물
KR102131359B1 (ko) * 2018-09-07 2020-07-07 오토텔릭바이오 주식회사 안정성이 향상된 의약 조성물
EP3632929A1 (en) * 2018-10-02 2020-04-08 Ospedale San Raffaele S.r.l. Antibodies and uses thereof
CN114651006A (zh) * 2019-11-15 2022-06-21 恩瑟拉有限责任公司 Tmem219抗体及其治疗性用途
US20230039165A1 (en) * 2019-11-21 2023-02-09 Enthera S.R.L. Igfbp3 antibodies and therapeutic uses thereof
CN114732896B (zh) * 2022-06-09 2022-09-02 广东省科学院微生物研究所(广东省微生物分析检测中心) 骨骼肌分泌因子Thbs4在制备改善系统糖脂代谢药物中的应用

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US5215534A (en) 1991-12-02 1993-06-01 Lawrence De Harde Safety syringe system
GB9603256D0 (en) 1996-02-16 1996-04-17 Wellcome Found Antibodies
WO1997039032A1 (en) * 1996-04-17 1997-10-23 Neurocrine Biosciences, Inc. Ligand inhibitors of insulin-like growth factor binding proteins and methods of use therefor
US6066464A (en) 1996-12-10 2000-05-23 Diagnostic Systems Laboratories, Inc. Immunoassay of IGF family of peptides, their binding proteins and related molecules in dried whole blood filter paper spots
ATE296315T1 (de) 1997-06-24 2005-06-15 Genentech Inc Galactosylierte glykoproteine enthaltende zusammensetzungen und verfahren zur deren herstellung
CA2307166A1 (en) 1997-10-31 1999-05-14 Genentech, Inc. Methods and compositions comprising glycoprotein glycoforms
EP1071700B1 (en) 1998-04-20 2010-02-17 GlycArt Biotechnology AG Glycosylation engineering of antibodies for improving antibody-dependent cellular cytotoxicity
US6448086B1 (en) 2000-01-18 2002-09-10 Diagnostic Systems Laboratories, Inc. Insulin-like growth factor system and cancer
EP1290162A4 (en) 2000-05-17 2005-08-17 Univ Oregon Health Sciences INDUCTION OF APOPTOSIS AND INHIBITION OF CELL GROWTH BY PROTEIN 4.33 (P4.33)
CA2421447C (en) 2000-09-08 2012-05-08 Universitat Zurich Collections of repeat proteins comprising repeat modules
AU2002232593A1 (en) 2000-10-27 2002-05-06 Oregon Health And Science University Novel mutant igbp-3 molecules that do not bind to igfs, but retain their ability to functionally bind igfbp-3 receptor
DE60143544D1 (de) 2000-12-12 2011-01-05 Medimmune Llc Moleküle mit längeren halbwertszeiten, zusammensetzungen und deren verwendung
WO2003011878A2 (en) 2001-08-03 2003-02-13 Glycart Biotechnology Ag Antibody glycosylation variants having increased antibody-dependent cellular cytotoxicity
EP1443961B1 (en) 2001-10-25 2009-05-06 Genentech, Inc. Glycoprotein compositions
US20040093621A1 (en) 2001-12-25 2004-05-13 Kyowa Hakko Kogyo Co., Ltd Antibody composition which specifically binds to CD20
US9296820B2 (en) 2003-11-05 2016-03-29 Roche Glycart Ag Polynucleotides encoding anti-CD20 antigen binding molecules with increased Fc receptor binding affinity and effector function
US7521541B2 (en) 2004-09-23 2009-04-21 Genetech Inc. Cysteine engineered antibodies and conjugates
WO2006113880A2 (en) 2005-04-19 2006-10-26 The Trustees Of Columbia University In The City Of New York Intact igfbp-3 as a colon cancer risk factor in patients with inflammatory bowel disease
CN101370525B (zh) 2005-08-19 2013-09-18 Abbvie公司 双重可变结构域免疫球蛋白及其用途
WO2008153788A2 (en) * 2007-05-30 2008-12-18 Albert Einstein College Of Medicine Of Yeshiva University Treatment of type 2 diabetes, metabolic syndrome, myocardial injury and neurodegeneration with humanin and analogs thereof
KR101860963B1 (ko) 2010-04-23 2018-05-24 제넨테크, 인크. 이종다량체 단백질의 생산
US9427531B2 (en) 2010-06-28 2016-08-30 Sanofi-Aventis Deutschland Gmbh Auto-injector
WO2012113900A1 (en) 2011-02-24 2012-08-30 INSERM (Institut National de la Santé et de la Recherche Médicale) Igfbp-3 derivatives and uses thereof
HK1202587A1 (en) * 2011-12-15 2015-10-02 The Royal Institution For The Advancement Of Learning/Mcgill University Soluble igf receptor fc fusion proteins and uses thereof
WO2013152989A2 (en) 2012-04-10 2013-10-17 Eth Zurich Biomarker assay and uses thereof for diagnosis, therapy selection, and prognosis of cancer
US9248242B2 (en) 2012-04-20 2016-02-02 Safety Syringes, Inc. Anti-needle stick safety device for injection device
US20140155827A1 (en) 2012-12-03 2014-06-05 Mylan, Inc. Medicament information system and method
US20160011207A1 (en) 2012-12-07 2016-01-14 Virginia Commonwealth University Diagnosis and therapy of chronic inflammation-induced disorders
US10005776B2 (en) 2014-10-23 2018-06-26 Janssen Pharmaceutica Nv Compounds as NIK inhibitors
AU2016272045B2 (en) 2015-06-04 2018-04-19 Ospedale San Raffaele Srl Inhibitor of IGFBP3/TMEM219 axis and diabetes
NZ738100A (en) 2015-06-04 2019-09-27 Ospedale San Raffaele Srl Igfbp3 and uses thereof

Also Published As

Publication number Publication date
US20210169973A1 (en) 2021-06-10
US11020453B2 (en) 2021-06-01
IL256096B (en) 2018-08-30
CA2988011A1 (en) 2016-12-08
JP2018516975A (ja) 2018-06-28
BR112017025998A2 (pt) 2018-08-14
US20180243367A1 (en) 2018-08-30
WO2016193497A1 (en) 2016-12-08
KR20180011842A (ko) 2018-02-02
MX367312B (es) 2019-08-14
CA2988011C (en) 2021-03-23
AU2016272045B2 (en) 2018-04-19
CN107921132B (zh) 2021-05-07
AU2016272045A1 (en) 2018-01-18
MX2017015617A (es) 2018-11-09
US20180169184A1 (en) 2018-06-21
IL256096A (en) 2018-01-31
KR101978765B1 (ko) 2019-05-15
JP6360265B2 (ja) 2018-07-18
EA033821B1 (ru) 2019-11-29
NZ738389A (en) 2019-02-22
CN107921132A (zh) 2018-04-17
HK1249449A1 (en) 2018-11-02

Similar Documents

Publication Publication Date Title
EA201792641A1 (ru) Ингибитор оси igfbp3/tmem219 и диабет
EA201890325A1 (ru) Пептидные ингибиторы рецептора интерлейкина-23 и их применение для лечения воспалительных заболеваний
BR112019006160A2 (pt) composições e métodos para o tratamento das condições oftálmicas
EA201790398A1 (ru) Способы лечения заболевания печени
MX384792B (es) Inhibidores de desmetilasa especifica de lisina 1 (lsd1).
MX377273B (es) Ciclopropilamina como inhibidor de la desmetilasa 1 específica de lisinas (lsd1).
EA201791775A1 (ru) Цистеиновая протеаза
MX2018016057A (es) Composiciones y metodos para tratar enfermedades cardiovasculares.
EA201691134A1 (ru) Новые ингибиторы глутаминазы
EA201591278A1 (ru) Композиции, содержащие c1-inh, и способы профилактики и лечения расстройств, ассоциированых с дефицитом ингибитора с1 эстеразы
CY1124406T1 (el) Αζασετρονη για χρηση στη θεραπεια της απωλειας ακοης
SG10201808940WA (en) Nox inhibitor and nfкb inhibitor containing methoxyflavone
EA201790142A1 (ru) Лечение лейкоза ингибиторами гистондеацетилазы
FR3021970B1 (fr) Anticorps dirige contre la galectine 9 et inhibiteur de l'activite suppressive des lymphocytes t regulateurs
EP3790867A4 (en) KDM1A INHIBITORS FOR THE TREATMENT OF DISEASE
EA201891539A1 (ru) Соединения, ингибирующие металлоферменты
EA202091731A1 (ru) Ингибиторы аутотаксина и их применения
EA201890728A3 (ru) Лечение ингибиторами ntcp атеросклероза, первичного билиарного цирроза и заболевания, связанного с nrlp3-инфламмасомами
EA201792157A1 (ru) Имидазопиразиноны в качестве ингибиторов pde1
EA202091865A1 (ru) Композиции и способы для снижения экспрессии tau
EA201891664A1 (ru) Составы/композиции, содержащие ингибитор btk
EA201892287A1 (ru) Фармацевтические комбинации для лечения рака
MX382996B (es) Inhibidores de pcna
EA201792610A1 (ru) Способ лечения неврологического заболевания
UA124939C2 (uk) СПОСІБ ЗБІЛЬШЕННЯ КОНЦЕНТРАЦІЇ ДЕЗОКСІУРИДИНУ (dUrd) В ПЛАЗМІ У СУБ’ЄКТА-ЛЮДИНИ

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG TJ TM RU